HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocol

Introduction Despite radical prostatectomy (RP) and radiotherapy (RT) being established treatments for localised prostate cancer, a significant number of patients experience recurrent disease. While conventionally fractionated RT is still being used as a standard treatment in the postoperative setti...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniel Zwahlen, Thomas Zilli, Etienne Mathier, Alexander Althaus, Jens Lustenberger, Constantinos Zamboglou, Berardino De Bari, Daniel M Aebersold, Matthias Guckenberger, Mohamed Shelan
Format: Article
Language:English
Published: BMJ Publishing Group 2024-01-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/1/e075846.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850025788193112064
author Daniel Zwahlen
Thomas Zilli
Etienne Mathier
Alexander Althaus
Jens Lustenberger
Constantinos Zamboglou
Berardino De Bari
Daniel M Aebersold
Matthias Guckenberger
Mohamed Shelan
author_facet Daniel Zwahlen
Thomas Zilli
Etienne Mathier
Alexander Althaus
Jens Lustenberger
Constantinos Zamboglou
Berardino De Bari
Daniel M Aebersold
Matthias Guckenberger
Mohamed Shelan
author_sort Daniel Zwahlen
collection DOAJ
description Introduction Despite radical prostatectomy (RP) and radiotherapy (RT) being established treatments for localised prostate cancer, a significant number of patients experience recurrent disease. While conventionally fractionated RT is still being used as a standard treatment in the postoperative setting, ultra-hypofractionated RT has emerged as a viable option with encouraging results in patients with localised disease in the primary setting. In addition, recent technological advancements in RT delivery and precise definition of isolated macroscopic recurrence within the prostate bed using prostate-specific membrane antigen-positron emission tomography (PSMA-PET) and multiparametric MRI (mpMRI) allow the exploration of ultra-hypofractionated schedules in the salvage setting using five fractions.Methods and analysis In this single-arm prospective phase II multicentre trial, 36 patients with node-negative prostate adenocarcinoma treated with RP at least 6 months before trial registration, tumour stage pT2a–3b, R0–1, pN0 or cN0 according to the UICC TNM 2009 and evidence of measurable local recurrence within the prostate bed detected by PSMA PET/CT and mpMRI within the last 3 months, will be included. The patients will undergo focal ultra-hypofractionated salvage RT with 34 Gy in five fractions every other day to the site of local recurrence in combination with 6 months of androgen deprivation therapy. The primary outcome of this study is biochemical relapse-free survival at 2 years. Secondary outcomes include acute side effects (until 90 days after the end of RT) of grade 3 or higher based on Common Terminology Criteria for Adverse Events V.5, progression-free survival, metastasis-free survival, late side effects and the quality of life (based on European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30, QLQ-PR25).Ethics and dissemination The study has received ethical approval from the Ethics Commission of the Canton of Bern (KEK-BE 2022-01026). Academic dissemination will occur through publications and conference presentations.Trial registration number NCT05746806.
format Article
id doaj-art-053238934fdf43a28d2f5ea8e9b5bfc9
institution DOAJ
issn 2044-6055
language English
publishDate 2024-01-01
publisher BMJ Publishing Group
record_format Article
series BMJ Open
spelling doaj-art-053238934fdf43a28d2f5ea8e9b5bfc92025-08-20T03:00:44ZengBMJ Publishing GroupBMJ Open2044-60552024-01-0114110.1136/bmjopen-2023-075846HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocolDaniel Zwahlen0Thomas Zilli1Etienne Mathier2Alexander Althaus3Jens Lustenberger4Constantinos Zamboglou5Berardino De Bari6Daniel M Aebersold7Matthias Guckenberger8Mohamed Shelan9Department of Radiation Oncology, Kantonsspital Winterthur, Winterthur, SwitzerlandDepartment of Radiation Oncology, Oncological Institute of Southern Switzerland, EOC, Bellinzona, SwitzerlandDepartment of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, SwitzerlandDepartment of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, SwitzerlandDepartment of Radiation Oncology, University Hospital Basel, Basel, SwitzerlandGerman Oncology Center, European University Cyprus, Limassol, CyprusDepartment of Radiation Oncology, Réseau hospitalier neuchâtelois, Neuchatel, SwitzerlandDepartment of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, SwitzerlandUniversity Hospital Zurich, Zurich, SwitzerlandDepartment of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, SwitzerlandIntroduction Despite radical prostatectomy (RP) and radiotherapy (RT) being established treatments for localised prostate cancer, a significant number of patients experience recurrent disease. While conventionally fractionated RT is still being used as a standard treatment in the postoperative setting, ultra-hypofractionated RT has emerged as a viable option with encouraging results in patients with localised disease in the primary setting. In addition, recent technological advancements in RT delivery and precise definition of isolated macroscopic recurrence within the prostate bed using prostate-specific membrane antigen-positron emission tomography (PSMA-PET) and multiparametric MRI (mpMRI) allow the exploration of ultra-hypofractionated schedules in the salvage setting using five fractions.Methods and analysis In this single-arm prospective phase II multicentre trial, 36 patients with node-negative prostate adenocarcinoma treated with RP at least 6 months before trial registration, tumour stage pT2a–3b, R0–1, pN0 or cN0 according to the UICC TNM 2009 and evidence of measurable local recurrence within the prostate bed detected by PSMA PET/CT and mpMRI within the last 3 months, will be included. The patients will undergo focal ultra-hypofractionated salvage RT with 34 Gy in five fractions every other day to the site of local recurrence in combination with 6 months of androgen deprivation therapy. The primary outcome of this study is biochemical relapse-free survival at 2 years. Secondary outcomes include acute side effects (until 90 days after the end of RT) of grade 3 or higher based on Common Terminology Criteria for Adverse Events V.5, progression-free survival, metastasis-free survival, late side effects and the quality of life (based on European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30, QLQ-PR25).Ethics and dissemination The study has received ethical approval from the Ethics Commission of the Canton of Bern (KEK-BE 2022-01026). Academic dissemination will occur through publications and conference presentations.Trial registration number NCT05746806.https://bmjopen.bmj.com/content/14/1/e075846.full
spellingShingle Daniel Zwahlen
Thomas Zilli
Etienne Mathier
Alexander Althaus
Jens Lustenberger
Constantinos Zamboglou
Berardino De Bari
Daniel M Aebersold
Matthias Guckenberger
Mohamed Shelan
HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocol
BMJ Open
title HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocol
title_full HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocol
title_fullStr HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocol
title_full_unstemmed HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocol
title_short HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocol
title_sort hypofocal srt trial ultra hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy single arm phase ii study clinical trial protocol
url https://bmjopen.bmj.com/content/14/1/e075846.full
work_keys_str_mv AT danielzwahlen hypofocalsrttrialultrahypofractionatedfocalsalvageradiotherapyforisolatedprostatebedrecurrenceafterradicalprostatectomysinglearmphaseiistudyclinicaltrialprotocol
AT thomaszilli hypofocalsrttrialultrahypofractionatedfocalsalvageradiotherapyforisolatedprostatebedrecurrenceafterradicalprostatectomysinglearmphaseiistudyclinicaltrialprotocol
AT etiennemathier hypofocalsrttrialultrahypofractionatedfocalsalvageradiotherapyforisolatedprostatebedrecurrenceafterradicalprostatectomysinglearmphaseiistudyclinicaltrialprotocol
AT alexanderalthaus hypofocalsrttrialultrahypofractionatedfocalsalvageradiotherapyforisolatedprostatebedrecurrenceafterradicalprostatectomysinglearmphaseiistudyclinicaltrialprotocol
AT jenslustenberger hypofocalsrttrialultrahypofractionatedfocalsalvageradiotherapyforisolatedprostatebedrecurrenceafterradicalprostatectomysinglearmphaseiistudyclinicaltrialprotocol
AT constantinoszamboglou hypofocalsrttrialultrahypofractionatedfocalsalvageradiotherapyforisolatedprostatebedrecurrenceafterradicalprostatectomysinglearmphaseiistudyclinicaltrialprotocol
AT berardinodebari hypofocalsrttrialultrahypofractionatedfocalsalvageradiotherapyforisolatedprostatebedrecurrenceafterradicalprostatectomysinglearmphaseiistudyclinicaltrialprotocol
AT danielmaebersold hypofocalsrttrialultrahypofractionatedfocalsalvageradiotherapyforisolatedprostatebedrecurrenceafterradicalprostatectomysinglearmphaseiistudyclinicaltrialprotocol
AT matthiasguckenberger hypofocalsrttrialultrahypofractionatedfocalsalvageradiotherapyforisolatedprostatebedrecurrenceafterradicalprostatectomysinglearmphaseiistudyclinicaltrialprotocol
AT mohamedshelan hypofocalsrttrialultrahypofractionatedfocalsalvageradiotherapyforisolatedprostatebedrecurrenceafterradicalprostatectomysinglearmphaseiistudyclinicaltrialprotocol